Compare BUR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | IVA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Guernsey | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | BUR | IVA |
|---|---|---|
| Price | $4.27 | $4.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $13.58 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 1.8M | 699.1K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $413,360,000.00 | N/A |
| Revenue This Year | $104.62 | N/A |
| Revenue Next Year | N/A | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.59 | $3.35 |
| 52 Week High | $14.14 | $7.98 |
| Indicator | BUR | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 55.72 |
| Support Level | $3.96 | $4.11 |
| Resistance Level | $4.54 | $4.70 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 45.38 | 62.50 |
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.